申请人:Byk Gulden Lomberg Chemische Fabrik GmbH
公开号:US04243678A1
公开(公告)日:1981-01-06
Compounds of the formula ##STR1## wherein R is (a) optionally-substituted and optionally-hydrogenated biphenylyl, (b) optionally-substituted and optionally-hydrogenated bicyclic aryl having from 8 to 12 ring carbon atoms or (c) a radical of the formula ##STR2## R.sup.1 is aliphatic hydrocarbyl, alicyclic hydrocarbyl or optionally-substituted phenyl; R.sup.2 is --H or lower aliphatic hydrocarbyl; R.sup.3 is --H, lower alkyl, cycloalkyl, optionally-substituted phenyl or, with R.sup.4, alkylene; R.sup.4 is lower alkyl, cycloalkyl, optionally-substituted phenyl, optionally-(nuclearly)-substituted phenalkyl or, with R.sup.3, alkylene; or R.sup.2,R.sup.3 and R.sup.4, together with the carbon to which each is bound, are adamantyl; and n is 3, 4 or 5; and salts thereof with a base are pharmacologically active. Esters thereof are valuable intermediates for the preparation of the pharmacologically-active compounds. Physiologically-acceptable embodiments are administered, e.g., in the form of an appropriate pharmaceutical composition to warm-blooded animals for protection against and treatment for stomach, intestine, pancreas, bile and liver disorders. Syntheses of pharmacologically-active components, transforming toxic embodiments to physiologically-acceptable principles, compounding such principles into pharmaceutical compositions and using such principles for preventing and treating the noted disorders are discussed.
该公式化合物的化合物##STR1##其中R是(a)选择性取代和选择性氢化的联苯基,(b)选择性取代和选择性氢化的含有8至12个环碳原子的双环芳基,或(c)具有式##STR2##的基团R.sup.1是脂肪烃基,脂环烃基或选择性取代苯基;R.sup.2是--H或较低的脂肪烃基;R.sup.3是--H,较低的烷基,环烷基,选择性取代苯基或与R.sup.4一起,烷基;R.sup.4是较低的烷基,环烷基,选择性取代苯基,选择性-(核)-取代苯基或与R.sup.3一起,烷基;或R.sup.2,R.sup.3和R.sup.4,与每个结合的碳一起,是三环戊烷基;n为3、4或5;及其与碱的盐具有药理活性。其酯是制备具有药理活性的化合物的有价值的中间体。生理可接受的实施例被施用,例如,以适当的药物组合的形式给温血动物,用于预防和治疗胃、肠、胰腺、胆汁和肝脏疾病。讨论了药理活性成分的合成,将有毒实施例转化为生理可接受的原则,将这些原则混合成药物组合物,并将这些原则用于预防和治疗上述疾病。